Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Usefulness of novel potassium adsorbents (SZC) in hyperkalemia patients with chronic kidney disease
jRCT1021210015Active, not recruiting
- Sponsor
- Hirosaki University
- Start
- Aug 2021
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of sodium zirconium cyclosilicate in chronic kidney disease (CKD) and hyperkalemia, sponsored by Hirosaki University. Primary endpoint: Compliance rate of SZC. Started Aug 2021; status: active, not recruiting.
02
Drugs
sodium zirconium cyclosilicate
03
Conditions
chronic kidney disease (CKD)hyperkalemia
Beyond the preview
Go deeper on jRCT1021210015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1021210015.